Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

140 7 Immunosuppresive Factors in Cancer
B. Pulendran and K. Palucka. 2000.
Immunobiology of dendritic cells.
Annu. Rev. Immunol. 18: 767.
67 Yamaguchi,Y., H. Tsumura, M. Miwa
and K. Inaba. 1997. Contrasting effects
of TGF-b1 and TNF-a on the development
of dendritic cells from progenitors
in mouse bone marrow. Stem Cells
15: 144.
68 Lee,W. C., C. Zhong, S. Qian,Y. Wan,
J. Gauldie, Z. Mi, P. D. Robbins,
A. W. Thomson and L. Lu. 1998. Phenotype,
function and in vivo migration
and survival of allogeneic dendritic cell
progenitors genetically engineered to
express TGF-b. Transplantation 66:
1810.
69 Sato, K., H. Kawasaki, H. Nagayama,
M. Enomoto, C. Morimoto, K. Tadokoro,
T. Juji and T. A. Takahashi.
2000. TGF-b1 reciprocally controls chemotaxis
of human peripheral blood
monocyte-derived dendritic cells via
chemokine receptors. J. Immunol. 164:
2285.
70 Won, J., H. Kim, E. J. Park,Y. Hong,
S. J. Kim and Y. Yun. 1999. Tumorigenicity
of mouse thymoma is suppressed
by soluble type II transforming growth
factor b receptor therapy. Cancer Res.
59: 1273.
71 Engel, S., S. Isenmann, M. Stander,
J. Rieger, M. Bahr and M. Weller.
1999. Inhibition of experimental rat
glioma growth by decorin gene transfer
is associated with decreased microglial
infiltration. J. Neuroimmunol. 99: 13.
72 Stander, M., U. Naumann, L. Dumitrescu,
M. Heneka, P. Loschmann,
E. Gulbins, J. Dichgans and
M. Weller. 1998. Decorin gene transfer-mediated
suppression of TGF-b
synthesis abrogates experimental malignant
glioma growth in vivo. Gene
Ther. 5: 1187.
73 Stander, M., U. Naumann,W. Wick
and M. Weller. 1999. Transforming
growth factor-b and p-21: multiple molecular
targets of decorin-mediated suppression
of neoplastic growth. Cell Tissue
Res. 296: 221.
74 Harthun, N. L., A. M. Weaver, L. H.
Brinckerhoff, D. H. Deacon,
S. L. Gonias and C. L. Slingluff, Jr.
1998. Activated a2-macroglobulin reverses
the immunosuppressive activity
in human breast cancer cell-conditioned
medium by selectively neutralizing
transforming growth factor-b in the
presence of interleukin-2. J. Immunother.
21: 85.
75 Wojtowicz-Praga, S., U. N. Verma,
L. Wakefield, J. M. Esteban, D. Hartmann,
A. Mazumder and U. M. Verma.
1996. Modulation of B16 melanoma
growth and metastasis by anti-transforming
growth factor b antibody and
interleukin-2. J. Immunother. Emphasis
Tumor Immunol. 19: 169.
76 Gridley, D. S., S. S. Sura, J. R. Uhm,
C. H. Lin and J. D. Kettering. 1993.
Effects of anti-transforming growth factor-b
antibody and interleukin-2 in tumor-bearing
mice. Cancer Biother. 8:
159.
77 Ohmori, T., J. L. Yang, J. O. Price and
C. L. Arteaga. 1998. Blockade of tumor
cell transforming growth factor-bs enhances
cell cycle progression and sensitizes
human breast carcinoma cells to
cytotoxic chemotherapy. Exp. Cell Res.
245: 350.
78 Park, J. A., E. Wang, R. A. Kurt,
S. F. Schluter, E. M. Hersh and
E. T. Akporiaye. 1997. Expression of an
antisense transforming growth factorb1
transgene reduces tumorigenicity of
EMT6 mammary tumor cells. Cancer
Gene Ther. 4: 42.
79 Liau, L. M., H. Fakhrai and
K. L. Black. 1998. Prolonged survival of
rats with intracranial C6 gliomas by
treatment with TGF-b antisense gene.
Neurol. Res. 20: 742.
80 Maggard, M., L. Meng, B. Ke,
R. Allen, L. Devgan and D. K. Imagawa.
2001. Antisense TGF-b2 immunotherapy
for hepatocellular carcinoma:
treatment in a rat tumor model.
Ann. Surg. Oncol 8: 32.
81 Naganuma, H., A. Sasaki, E. Satoh,
M. Nagasaka, S. Nakano, S. Isoe and
H. Nukui. 1998. Down-regulation of
transforming growth factor-b and interleukin-10
secretion from malignant
glioma cells by cytokines and anticancer
drugs. J. Neurooncol. 39: 227.